Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Inovio Pharmaceuticals Inc (INO)

98 + Investors. Track Smart Money conviction in INO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
1Q ▼
Buyers last Q
47%

Smart Money Signals — INO

Based on 98 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their INO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 91% of 3.0Y peak

91% of all-time peak
98 funds currently hold this stock — 91% of the 3.0-year high of 108 funds (reached 2025 Q1). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 9% fewer funds vs a year ago

fund count last 6Q
10 fewer hedge funds hold INO compared to a year ago (-9% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟠

More sellers than buyers — 47% buying

40 buying45 selling
Last quarter: 45 funds reduced or exited vs 40 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~18 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 23 → 25 → 18 → 18. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 32% long-term, 36% new

■ 32% conviction (2yr+) ■ 33% medium ■ 36% new
Of the 98 current holders: 31 (32%) held >2 years, 32 held 1–2 years, and 35 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
📊

Peak discovery — momentum slowing

19 → 23 → 25 → 18 → 18 new funds/Q
New funds entering each quarter: 23 → 25 → 18 → 18. INO is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
📊

Mixed cohorts — 5% veterans, 39% new entrants

■ 5% veterans ■ 57% 1-2yr ■ 39% new
Of 106 current holders: 5 (5%) held 2+ years, 60 held 1–2 years, 41 (39%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
🏆

Elite ownership — 59% AUM from top-100 funds

59% from top-100 AUM funds
22 of 98 holders are among the 100 largest funds by AUM, controlling 59% of total institutional value in INO. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — INO

In 2026 Q1, 40 hedge funds were net buyers of INO (18 opened a new position, 22 added to an existing one), while 45 reduced or exited (25 trimmed, 20 sold completely) — a 47% buyer ratio, indicating roughly balanced activity. 59% of total institutional value in INO is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 98.

Hedge Fund Ownership: INO

How many hedge funds hold INO — quarterly history vs. share price
Quarterly hedge fund ownership of INO vs. share price

Market Analysis: INO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: INO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Inovio Pharmaceuticals Inc (INO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much INO has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 80d ago
INO
-35.6%
XLV
+2.1%

INO outperformed XLV by -37.7% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 35d ago
INO
-13.8%
XLV
+3.2%

Since the filing became public, INO outperformed XLV by -17.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

7 top-rated funds 0 high-conviction
Consensus
3.9
/ 10
breadth
×
Elite
0.2
/ 10
conviction
Hedge Fund Positioning: INO
98 + Investors

Track Smart Money conviction in INO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 98 100 -2.0%
13F Shares 32M 34M -4.93%
Total Value $55M $59M -5.8%
New Positions 18 18 -
Increased Positions 21 27 -6
Closed Positions 20 18 +2
Reduced Positions 21 22 -1
Total Calls 5 5 -
Total Puts 3 2 50.0%
PUT/CALL Ratio 0.6 0.4 Bullish

Statistics: INO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

98 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in INO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 INO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Boxer Capital Management, LLC 0.54% 2,370,122 $4.1M
2 Diadema Partners LP 0.17% 562,665 $979K
3 ADAR1 Capital Management, LLC 0.15% 1,470,108 $2.6M
4 Green Alpha Advisors, LLC 0.11% 65,580 $114K
5 Eversept Partners, LP 0.09% 1,035,360 $1.8M
6 Persistent Asset Partners Ltd 0.09% 142,164 $247K
7 683 Capital Management, LLC 0.02% 248,790 $433K
8 Diadema Partners LP 0.02% 75,200 $131K
9 Diametric Capital, LP 0.01% 24,491 $43K
10 Gmt Capital Corp 0.01% 126,119 $219K
11 NINE MASTS CAPITAL Ltd 0.01% 26,317 $46K
12 XTX Topco Ltd 0.01% 212,677 $370K
13 Bridgeway Capital Management, LLC 0.01% 173,000 $301K
14 Janus Henderson Group plc 0.00% 3,308,406 $5.8M
15 Mayflower Financial Advisors, LLC 0.00% 12,559 $22K
16 Tower Research Capital LLC (TRC) 0.00% 55,491 $97K
17 D. E. Shaw & Co., Inc. 0.00% 2,212,819 $3.9M
18 Adage Capital Partners GP, L.L.C. 0.00% 804,958 $1.4M
19 Renaissance Technologies LLC 0.00% 643,777 $1.1M
20 Legacy Wealth Managment, LLC/ID 0.00% 1,356 $2K
21 Millennium Management LLC 0.00% 1,410,845 $2.5M
22 MCF Advisors LLC 0.00% 11,274 $20K
23 Fmr LLC 0.00% 9,339,614 $16.3M
24 Two Sigma Investments, LP 0.00% 390,384 $679K
25 Activest Wealth Management 0.00% 1,500 $3K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Inovio Pharmaceuticals Inc (INO)

What does the Smart Money Trend signal show for INO?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their INO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for INO?

More sellers than buyers — 47% buying: Last quarter: 45 funds reduced or exited vs 40 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for INO holders?

Elite ownership — 59% AUM from top-100 funds: 22 of 98 holders are among the 100 largest funds by AUM, controlling 59% of total institutional value in INO. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held INO?

Mixed — 32% long-term, 36% new: Of the 98 current holders: 31 (32%) held >2 years, 32 held 1–2 years, and 35 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Inovio Pharmaceuticals Inc (INO) following the 2026 Q1 hedge fund 13F filings?

As of today, INO has moved -13.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of -17.0%. Since the quarter end (March 31, 2026), INO has gained -35.6% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →